Results of several clinical studies carried out have shown that there are no harmful interactions between Isentress and Triumeq. As such, the two medications can be used simultaneously with no negative consequences.
Isentress is an antiretroviral medication created for the specific purpose of treating HIV and preventing the virus from replicating in adults and children. Although Isentress is mainly used for treating HIV, it can also be used as a preventive measure, i.e. as a part of post-exposure prophylaxis (PEP) treatment following exposure to the virus [1]. Thus, people who feel they have been exposed to HIV can visit a doctor or HIV clinic to get this medication in addition to other PEP treatments.
Isentress (raltegravir) should be taken orally and regularly, with or without food [2]. Patients who use this medication should avoid skipping doses. In a situation where a patient accidentally misses a dose, there is absolutely no need to double dose.
Before using this drug, one should contact a doctor in order to be completely certain that it is appropriate for the patient in question.
Triumeq is an antiretroviral meditation just like the above-mentioned tabs. However, its composition and mechanism of action are distinct from Isentress. Triumeq is a combination of three different substances: abacavir, dolutegravir, and lamivudine [3]. They join forces to carry out the drug’s purpose.
Triumeq is taken orally. It is still uncertain whether this medication is suitable for use in pregnant women. However, they should only take this medication if the benefits outweigh the potential risks. Patients ought to have a proper consultation with a doctor or health care provider before using this drug.
So far, only positive interactions have been observed in patients who combine these medications. Thus, they can be used simultaneously to treat HIV without adverse reactions.
However, this does not completely eliminate the possibility of side effects caused by such a mixture. This is due to the fact that certain interactions may not be relevant clinically in all patients combining drugs. Still, the combination of Isentress and Triumeq very rarely requires a therapy change. Dolutegravir is not expected to influence the levels of raltegravir. Raltegravir might slightly alter the levels of abacavir in the blood, but not in a way that can be considered dangerous. In the same vein, raltegravir doesn’t have any effect on the action mechanism of lamivudine.
It is still important to visit your doctor before using these drugs.